Background: Alteplase has been the accepted thrombolytic for acute ischemic stroke (AIS) for 25 years. However, recent data has emerged regarding tenectaplase as an alternative. Tenecteplase is a modified form of alteplase, with a lower cost and more favorable pharmacokinetic ...
Background: Intravenous alteplase is the current standard care for treatment of acute ischemic stroke (AIS) despite active debate on the research supporting its use. The window for its use has been restricted to <3h of symptom onset based on the ...
Background: The risk of a subsequent ischemic stroke in the first few months after an acute ischemic stroke or transient ischemic attack is approximately 5 to 10%. In these patients Aspirin has been used to prevent secondary ischemia, and trials ...
Background: The scientific process in medicine is complicated. Obtaining high-quality data to guide management requires hypothesis formulation, data to support the hypothesis and study replication. Time and again beneficial findings in therapeutic studies fail to be replicated in subsequent studies. ...
Background: Here we go again with another “Time is Brain,” acute ischemic stroke study. The authors start out by saying that earlier administration of intravenous tPA in acute ischemic stroke is associated with reduced mortality by the time of hospital ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
